BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 17848650)

  • 21. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.
    Schnyder G; Roffi M; Flammer Y; Pin R; Hess OM
    JAMA; 2002 Aug; 288(8):973-9. PubMed ID: 12190367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
    Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homocysteine and renal disease.
    van Guldener C; Robinson K
    Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study.
    Nanayakkara PW; van Guldener C; ter Wee PM; Scheffer PG; van Ittersum FJ; Twisk JW; Teerlink T; van Dorp W; Stehouwer CD
    Arch Intern Med; 2007 Jun; 167(12):1262-70. PubMed ID: 17592099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
    Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
    Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke.
    Liu X; Shi M; Xia F; Han J; Liu Z; Wang B; Yang F; Li L; Wu S; Wang L; Liu N; Lv Y; Zhao G
    Int J Stroke; 2015 Feb; 10(2):264-8. PubMed ID: 23490255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homocysteine lowering and cardiovascular events after acute myocardial infarction.
    Bønaa KH; Njølstad I; Ueland PM; Schirmer H; Tverdal A; Steigen T; Wang H; Nordrehaug JE; Arnesen E; Rasmussen K;
    N Engl J Med; 2006 Apr; 354(15):1578-88. PubMed ID: 16531614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homocysteine lowering with folic acid and B vitamins in vascular disease.
    Lonn E; Yusuf S; Arnold MJ; Sheridan P; Pogue J; Micks M; McQueen MJ; Probstfield J; Fodor G; Held C; Genest J;
    N Engl J Med; 2006 Apr; 354(15):1567-77. PubMed ID: 16531613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations.
    Green TJ; Skeaff CM; McMahon JA; Venn BJ; Williams SM; Devlin AM; Innis SM
    Br J Nutr; 2010 Jun; 103(11):1629-34. PubMed ID: 20089204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.
    Aisen PS; Schneider LS; Sano M; Diaz-Arrastia R; van Dyck CH; Weiner MF; Bottiglieri T; Jin S; Stokes KT; Thomas RG; Thal LJ;
    JAMA; 2008 Oct; 300(15):1774-83. PubMed ID: 18854539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials.
    Garcia Lopez M; Bønaa KH; Ebbing M; Eriksen EF; Gjesdal CG; Nygård O; Tell GS; Ueland PM; Meyer HE
    J Bone Miner Res; 2017 Oct; 32(10):1981-1989. PubMed ID: 28574605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial.
    Woodside JV; Yarnell JW; McMaster D; Young IS; Harmon DL; McCrum EE; Patterson CC; Gey KF; Whitehead AS; Evans A
    Am J Clin Nutr; 1998 May; 67(5):858-66. PubMed ID: 9583842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R; Armitage J
    Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid.
    Hong SY; Yang DH; Chang SK
    Am J Nephrol; 1998; 18(5):367-72. PubMed ID: 9730558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.
    de Jager CA; Oulhaj A; Jacoby R; Refsum H; Smith AD
    Int J Geriatr Psychiatry; 2012 Jun; 27(6):592-600. PubMed ID: 21780182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
    Bleie Ø; Semb AG; Grundt H; Nordrehaug JE; Vollset SE; Ueland PM; Nilsen DW; Bakken AM; Refsum H; Nygård OK
    J Intern Med; 2007 Aug; 262(2):244-53. PubMed ID: 17645592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
    Bostom AG; Carpenter MA; Kusek JW; Levey AS; Hunsicker L; Pfeffer MA; Selhub J; Jacques PF; Cole E; Gravens-Mueller L; House AA; Kew C; McKenney JL; Pacheco-Silva A; Pesavento T; Pirsch J; Smith S; Solomon S; Weir M
    Circulation; 2011 Apr; 123(16):1763-70. PubMed ID: 21482964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.